A history of ProZ92 from Said
Moady, president and CEO
My father had psoriasis for over thirty years and went to hospitals and doctors all over Israel and the Middle East, but he received no relief. As a last resort, he started researching natural alternatives. He read many ancient books and began experimenting with combinations of botanical extracts. After many years of research and experimentation, he arrived at the formula used today in the Pro Z92 compound.
He began helping others with the formula. On August, 23 1991, an article ran in Yedioth Ahronot, the main newspaper in Israel, about my father, entitled “The Secret of Mr. Moady,” discussing the amazing success my father was having in treating psoriasis and other skin conditions with natural botanicals. The next day, Saturday August 24, 1991, more than 250 people came from all over the country seeking help for their psoriasis problem.
I was visiting my father at the time. Concerned by the large numbers of people suffering from this disease and intrigued by his results, I decided to begin to collect anecdotal data on the effectiveness of my father’s formula. I asked some people with psoriasis if I could treat them, with the condition that I be allowed to take pictures before and after. I treated 15 patients, and the results were that 12 of the patients – 80% – were cleared. Next I initiated a scientific study, using a United States based team. In 1994, Dr. Jane Gibson of the Orlando Florida based Health Sciences Center started testing the Pro Z92 in vivo (with live animals) and in vitro (with cell culture study) with the coordination of Rutgers University chemist Dr. Thomas G. Hartman and our chemist professor David Kinder.
After 14 months of comprehensive Chemical Characterization and
testing of the Pro Z92 extract, Dr. Gibson concluded that compound inhibits the growth of the type of cells involved in psoriasis. Dr. Hartman concluded that Pro Z92 was novel. They indicated that prospects for future development were encouraging.
We then started additional studies. A toxicity study took more than two years and indicated no toxicity whatsoever. Our chemist, Professor David Kinder started the formulation, standardization and stability process for the compound, at the Ohio University College of Pharmacy. Two clinical trials were conducted, one by Taro Pharmaceuticals, in New York, in 2004; the second by Dr. Howard Yanofsky, a Canadian dermatologist, in 2004. Both indicated a high rate of success.
To date, thousands patients have been treated with a success rate of more than 75%.
Psoriasis is an autoimmune skin disorder resulting in excessive skin cell reproduction. The disease has several appearances but is most often characterized by raised, inflamed lesions covered with a scaly white build-up of dead skin cells. Nearly seven million people in the U.S. suffer from various forms of psoriasis.
Psoriasis is not just an inconvenience. It is a debilitating, painful, long-term condition.
Yet none of the current treatments, including topical steroids and immunosuppressant medications, offer consistent relief. Indeed, while there are many approved treatments, "No psoriasis therapy is universally effective alone or combined, and toxicity will vary" (the National Psoriasis Foundation).
Pro Z92 changes that. It is a safe, effective treatment with proven, lasting results.